Study identification

EU PAS number

EUPAS9462

Study ID

27127

Official title and acronym

Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for HR+ Women (BRAWO)

DARWIN EU® study

No

Study countries

Germany

Study description

BRAWO is a German, non-interventional study with a planned enrollment of 3,000 patients with HR+ advanced breast cancer receiving Everolimus+Exemestane according to the approved label.Main objectives of the BRAWO study are to extend knowledge in the following areas• Efficacy and the impact of physical activity on efficacy and quality of life in routine clinical care• Prophylaxis and management of stomatitis• Sequence of therapy and drug utilization when EVE+EXE is used in routine clinical care

Study status

Finalised
Research institutions and networks

Institutions

Multiple centres: 400 centres are involved in the study

Contact details

Novaratis Clinical Disclosure Office

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of interim report, if expected

Planned:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Novartis
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable